NCT06311656View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

October 4, 2024

Study Completion Date

October 4, 2024

Conditions
Healthy
Interventions
DRUG

LY4100511 (DC-853)

Administered orally fasted

DRUG

LY4100511 (DC-853)

Administered orally fasted.

DRUG

LY4100511 (DC-853)

Administered orally fed and fasted.

DRUG

LY4100511 (DC-853)

Administered orally fed and fasted.

DRUG

Placebo

Administered orally.

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors
lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT06311656 - A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants | Biotech Hunter | Biotech Hunter